--:--:--
Stockwatch Reports
…

News Reports / Healthcare / HTFL

HTFLHeartflow, Inc.

NasdaqGS · Healthcare · Mkt cap $4.3B · Avg vol 2.06M

$48.46

-11.46 (-19.13%)

Quote as of November 13, 2026, 5:46 PM ET

News Impact Report · Published November 13, 2026, 9:44 AM ET

HTFL: Heartflow Reports Q3 FY2026 Results — Wide Operating Loss Drives Shares Down 13%

Share

Price: $52.30 | Today's Change: -12.73%

What Happened

Heartflow, Inc. filed an 8-K with the SEC on November 12, 2026 (Items 2.02 and 9.01), disclosing its financial results for the third quarter of fiscal year 2026. The company reported revenue of $126.9 million for the quarter, alongside a net loss of $32.3 million and an operating loss of $46.3 million. Both basic and diluted loss per share came in at -$4.47, underscoring the depth of the gap between top-line activity and bottom-line profitability.

Why It Matters

The scale of the operating loss — $46.3 million against $126.9 million in revenue — means Heartflow is spending roughly $1.37 for every dollar it earns at the operating level this quarter. For investors, the key near-term question is whether the revenue base is growing fast enough to close that gap before the company's cash runway becomes a concern. The sharp single-day decline of nearly 13% in HTFL shares suggests the market viewed this result as worse than anticipated. With StockWatch's initiating coverage having been published in September 2026, this quarterly print gives investors their first material earnings data point since that coverage was initiated.

Analysis

The headline numbers reveal a company still firmly in investment mode, with operating costs running well ahead of revenue. At $126.9 million in quarterly revenue, Heartflow is not a small-scale operation — this is a meaningful commercial footprint — but the $46.3 million operating loss signals that the path to sustainable profitability remains a multi-quarter, if not multi-year, journey.

A few things are worth watching closely:

  • Gross margin trajectory: The structured data provided does not include gross profit figures, so it is not possible to determine from this filing alone how much of the operating loss stems from above-the-line costs versus operating expense investment (R&D, SG&A). That breakdown will be critical context.
  • Revenue growth rate: A single quarter's revenue figure in isolation tells us little about momentum. Whether $126.9 million represents acceleration or deceleration relative to prior quarters will be key to assessing whether operating leverage is building.
  • Cash position: The filing data provided here does not include a balance sheet snapshot. Investors will want to scrutinize the full 10-Q or earnings presentation materials for cash, equivalents, and any updated guidance on operating cash burn.

The severity of today's sell-off suggests the market had priced in a more favorable outcome, and the results have prompted a meaningful reset of near-term expectations. How management addresses the path to profitability — and whether it provides updated guidance — will be the central focus for investors in the days ahead.

Disclaimer

This report is a news and informational analysis based solely on data contained in Heartflow's publicly filed SEC disclosure and does not constitute investment advice. No buy, hold, or sell recommendation is made or implied. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decision.

Existing Coverage

StockWatch has full coverage on HTFL, published 2026-09-11. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-12. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1464521/000146452126000171/htfl-20261112x8k.htm

StockWatch initiated coverage · September 11, 2026

HTFL: Heartflow Brings AI-Guided Coronary Diagnostics Into the Cath Lab Mainstream

A high-growth medtech story priced for execution. HTFL trades at $48.67 with a $4.3B market cap, up 6.99% on the day and sitting near the top of its $20.13–$51.78 52-week range. The stock has more than doubled off its lows, reflecting accelerating adoption of AI-based coronary CT angiography (CCTA) analysis, but the current price already discounts several years of rapid revenue growth — leaving little margin for commercial missteps. **Loss-making today, but the trajectory matters more th

-0.4%

Read the full report →

-0.4%

Key Data

Last

$52.30

P&L ($)

$-7.63

P&L (%)

-12.73%

Day Range

$51.95 - $58.38

Volume

160.00K

Market Cap

$4.3B

Previous Close

$59.92

Open

$57.94

52 Week Range

$20.13 - $60.66

Shares Outstanding

86.95M

Public Float

68.01M

Average Volume

2.06M

As of November 13, 2026, 9:45 AM ET

Advertise here
Stockwatch Reports

Free stock market updates, top gainers & losers, and AI-generated stock analyses — updated daily. Real-time price movements, quotes, and coverage for German & U.S. stoc